Brandal, S.H.B.; Mo, T.; Fangberget, A.; Nilsen, L.B.; Geier, O.M.; Bjørndal, H.; Holmen, M.M.; Engebråten, O.; Garred, Ø.; Hole, K.H.;
et al. MRI for Predicting Response and 10-Year Outcome of Neoadjuvant Chemotherapy with or Without Additional Bevacizumab Treatment in HER2-Negative Breast Cancer. Cancers 2026, 18, 393.
https://doi.org/10.3390/cancers18030393
AMA Style
Brandal SHB, Mo T, Fangberget A, Nilsen LB, Geier OM, Bjørndal H, Holmen MM, Engebråten O, Garred Ø, Hole KH,
et al. MRI for Predicting Response and 10-Year Outcome of Neoadjuvant Chemotherapy with or Without Additional Bevacizumab Treatment in HER2-Negative Breast Cancer. Cancers. 2026; 18(3):393.
https://doi.org/10.3390/cancers18030393
Chicago/Turabian Style
Brandal, Siri Helene Bertelsen, Torgeir Mo, Anne Fangberget, Line Brennhaug Nilsen, Oliver Marcel Geier, Hilde Bjørndal, Marit Muri Holmen, Olav Engebråten, Øystein Garred, Knut Håkon Hole,
and et al. 2026. "MRI for Predicting Response and 10-Year Outcome of Neoadjuvant Chemotherapy with or Without Additional Bevacizumab Treatment in HER2-Negative Breast Cancer" Cancers 18, no. 3: 393.
https://doi.org/10.3390/cancers18030393
APA Style
Brandal, S. H. B., Mo, T., Fangberget, A., Nilsen, L. B., Geier, O. M., Bjørndal, H., Holmen, M. M., Engebråten, O., Garred, Ø., Hole, K. H., & Seierstad, T.
(2026). MRI for Predicting Response and 10-Year Outcome of Neoadjuvant Chemotherapy with or Without Additional Bevacizumab Treatment in HER2-Negative Breast Cancer. Cancers, 18(3), 393.
https://doi.org/10.3390/cancers18030393
